ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
예방 백신 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 이러한 예상 성장에 기여하는 요인으로는 백신 연구를 위한 자금 급증, 감염병에 대한 부담 증가, 맞춤형 백신에 대한 수요 증가, 정부의 지원 확대, 첨단 백신 기술의 광범위한 채택 등이 있습니다. 예측 기간 중에 예상되는 주요 동향으로는 mRNA 기반의 백신 플랫폼의 진화, 차세대 전달 시스템의 개발, 나노입자 백신 제제의 획기적 진보, 백신 개발에 있어서의 인공지능의 이용, 온도 관리된 백신 물류의 개선 등을 들 수 있습니다.
감염증의 유행 확대는 예방백신 시장의 확대를 촉진할 것으로 예측됩니다. 도시화 증가, 전 세계 여행, 항균제 내성과 같은 요인들이 이러한 질병의 확산 속도를 높이고 관리의 어려움을 증가시키는 데 기여합니다. 예방 백신은 감염증이 발생하기 전에 병원체를 인식하고 격퇴하도록 면역계를 자극함으로써 결국 질병의 발생과 전파를 감소시키고 감염증을 제어하는데 중요한 역할을 하고 있습니다. Australian Institute of Health and Welfare는 2022년, 호주에서 감염증으로 1만 5,770명 이상의 사망자가 발생했으며, 하부 호흡기 질환으로 의한 사망이 약 3분의 1을 차지하고 있다고 보고했습니다. 결과적으로 감염병에 대한 부담 증가가 예방 백신 시장의 성장을 촉진하고 있습니다.
예방 백신 시장의 기업은 백신의 효능을 높이고, 안전성을 개선하고, 개발 기간을 단축하고, 신흥 감염에 대한 폭넓은 방어를 확보하기 위해 최첨단 mRNA 기술 플랫폼을 포함한 기술적 진보에 점점 주력하고 있습니다. Moderna Inc.는 새로운 COVID-19 백신인 mNEXSPIKE(mRNA-1283)의 FDA 승인을 받았습니다. mNEXSPIKE의 발매는 차세대 mRNA 백신 기술에 있어서의 현저한 진보이며, 이전의 것에 비해 안정성과 보존의 용이성이 향상하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 예방 백신 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계 예방 백신 시장 : 성장률 분석
세계 예방 백신 시장 실적 : 규모와 성장, 2019-2024
세계 예방 백신 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 예방 백신 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 예방 백신 시장 : 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
Live Or Attenuated 백신s
Inactivated 백신s
Toxoid 백신s
Subunit 백신s
Conjugate 백신s
DNA 백신s
Recombinant Vector 백신s
세계의 예방 백신 시장 : 질환 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
폐렴구균
Poliovirus
간염
인플루엔자
홍역
풍진
기타 질병의 유형
세계의 예방 백신 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
클리닉
약국
기타 유통 채널
세계의 예방 백신 시장 : 연령층별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
소아과
성인용
고령자
세계의 예방 백신 시장 : 생백신 또는 약독화 백신유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
Measles, Mumps, and Rubella (MMR) 백신
Varicella (Chickenpox) 백신
Oral Polio 백신 (OPV)
Yellow Fever 백신
Rotavirus 백신
Bacillus Calmette-Guerin (BCG) 백신
세계의 예방 백신 시장 : 불활화 백신유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
Inactivated Poliovirus 백신 (IPV)
A형 간염 백신
광견병 백신
인플루엔자(비활성화) 백신
일본 뇌염 백신
세계의 예방 백신 시장 : Toxoid 백신s 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
파상풍 Toxoid 백신s
Diphtheria Toxoid 백신
백일해 백신
세계의 예방 백신 시장 : 서브 유닛 백신유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
B형 간염 백신
인유두종 바이러스(HPV) 백신
백일해(무세포) 백신
인플루엔자(재조합 단백질) 백신
세계의 예방 백신 시장 : 결합 백신유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
폐렴구균 결합 백신(PCV)
Hib(인플루엔자균 b형) 백신
수막염균 결합 백신
세계의 예방 백신 시장 DNA 백신유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
지카바이러스 DNA 백신
Cytomegalovirus (CMV) DNA 백신
감염증 DNA 백신
세계의 예방 백신 시장 : 재조합 벡터 백신유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
에볼라 백신(rVSV-ZEBOV)
COVID-19 재조합 벡터 백신
뎅기열 재조합 벡터 백신
제7장 지역별/국가별 분석
세계의 예방 백신 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 예방 백신 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
예방 백신 시장 : 경쟁 구도
예방 백신 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Johnson & Johnson Services Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi Pasteur SA : 개요, 제품 및 서비스, 전략 및 재무 분석
AstraZeneca plc : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
GlaxoSmithKline plc(GSK)
Takeda Pharmaceutical Company Limited
Moderna Inc.
CSL Limited
Novavax Inc.
Emergent BioSolutions Inc.
Dynavax Technologies Corporation
Serum Institute of India Pvt. Ltd.
Vaxcyte Inc.
Bavarian Nordic A/S
Valneva SE
Panacea Biotec Ltd.
Inovio Pharmaceuticals Inc.
Mitsubishi Tanabe Pharma Corporation
Afrigen Biologics and Vaccines(Pty) Ltd.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
예방 백신 시장(2029년) : 새로운 기회를 제공하는 국가
예방 백신 시장(2029년) : 새로운 기회를 제공하는 부문
예방 백신 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
SHW
영문 목차
영문목차
Preventive vaccines are biological preparations intended to safeguard individuals from infectious diseases by activating the immune system to identify and combat specific pathogens. These vaccines are administered prior to exposure to a disease-causing agent to either prevent infection or lessen its severity. Preventive vaccines serve as a vital component of public health strategies by helping control the transmission of infectious diseases.
The primary categories of preventive vaccines include live or attenuated vaccines, inactivated vaccines, toxoid vaccines, subunit vaccines, conjugate vaccines, DNA vaccines, and recombinant vector vaccines. Live or attenuated vaccines are developed from weakened versions of viruses or bacteria, capable of inducing a strong and long-lasting immune response without causing the actual disease. These vaccines target diseases such as pneumococcal infections, poliovirus, hepatitis, influenza, measles, rubella, and others. They are distributed through various channels including hospitals, clinics, pharmacies, and other medical outlets. The vaccines are formulated for different age groups, including pediatric, adult, and geriatric populations.
The preventive vaccines market research report is one of a series of new reports from The Business Research Company that provides preventive vaccines market statistics, including the preventive vaccines industry global market size, regional shares, competitors with the preventive vaccines market share, detailed preventive vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the preventive vaccines industry. This preventive vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The preventive vaccines market size has grown strongly in recent years. It will grow from $75.94 billion in 2024 to $81.39 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The historical growth of the market was driven by increased government support, heightened awareness of infectious diseases, expansion of global immunization campaigns, continuous progress in vaccine technologies, and a growing focus on childhood immunizations.
The preventive vaccines market size is expected to see strong growth in the next few years. It will grow to $106.47 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. Contributing factors to this projected growth include a surge in funding for vaccine research, a rising burden of infectious diseases, an uptick in demand for customized vaccines, expanded governmental backing, and wider adoption of cutting-edge vaccine technologies. Key trends anticipated during the forecast period include the evolution of mRNA-based vaccine platforms, the development of next-generation delivery systems, breakthroughs in nanoparticle vaccine formulations, the use of artificial intelligence in vaccine development, and improvements in temperature-controlled vaccine logistics.
The growing prevalence of infectious diseases is expected to drive the expansion of the preventive vaccines market. Infectious diseases are illnesses caused by pathogenic microorganisms such as bacteria, viruses, fungi, or parasites, which can spread through person-to-person contact or environmental exposure. Factors such as increasing urbanization, global travel, and antimicrobial resistance contribute to the accelerated spread and increased difficulty in managing these diseases. Preventive vaccines play a critical role in controlling infectious diseases by stimulating the immune system to recognize and fight off pathogens before infection occurs, ultimately reducing disease incidence and transmission. For example, in July 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that in 2022, infectious diseases were responsible for over 15,770 deaths in the country, with lower respiratory infections accounting for approximately one-third of these non-notifiable disease deaths. Consequently, the rising burden of infectious diseases is fueling the growth of the preventive vaccines market.
Companies in the preventive vaccines market are increasingly focusing on technological advancements, including cutting-edge mRNA technology platforms, to enhance vaccine efficacy, improve safety, accelerate development timelines, and ensure broader protection against emerging infectious disease variants. mRNA technology involves the use of messenger RNA to prompt cells to produce specific proteins that trigger targeted immune responses. For instance, in March 2025, Moderna Inc., a biotechnology firm based in the United States, received FDA approval for mNEXSPIKE (mRNA-1283), a new COVID-19 vaccine. This vaccine is authorized for adults aged 65 and older, as well as individuals aged 12-64 who have one or more CDC-defined risk factors. The release of mNEXSPIKE represents a notable advancement in next-generation mRNA vaccine technology, offering improved stability and ease of storage compared to earlier iterations. This innovation is anticipated to enhance vaccine accessibility and distribution, especially in underserved and remote regions.
In April 2024, European LifeCare Group, a UK-based vaccination services provider, acquired PreventVaccins B.V. for an undisclosed sum. This acquisition enabled European LifeCare Group to expand its presence in the European vaccination market and strengthen its services by incorporating the expertise and operations of PreventVaccins B.V. Based in the Netherlands, PreventVaccins B.V. is a biotechnology company specializing in the development of preventive vaccines targeting infectious diseases.
Major players in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, and Afrigen Biologics and Vaccines (Pty) Ltd.
North America was the largest region in the preventive vaccines market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in preventive vaccines report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the preventive vaccines market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The preventive vaccines market consists of sales of toxoid vaccines, plant-based vaccines, and combination vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Preventive Vaccines Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on preventive vaccines market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for preventive vaccines ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The preventive vaccines market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Live Or Attenuated Vaccines; Inactivated Vaccines; Toxoid Vaccines; Subunit Vaccines; Conjugate Vaccines; DNA Vaccines; Recombinant Vector Vaccines
2) By Disease Type: Pneumococcal; Poliovirus; Hepatitis; Influenza; Measles; Rubella; Other Disease Types
3) By Age Group: Pediatric; Adult; Geriatric
4) By Distribution Channel: Hospitals; Clinics; Pharmacies; Other Distribution Channels
Subsegments:
1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine; Varicella (Chickenpox) Vaccine; Oral Polio Vaccine (OPV); Yellow Fever Vaccine; Rotavirus Vaccine; Bacillus Calmette-Guerin (BCG) Vaccine
2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV); Hepatitis A Vaccine; Rabies Vaccine; Influenza (Inactivated) Vaccine; Japanese Encephalitis Vaccine
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Preventive Vaccines Market Characteristics
3. Preventive Vaccines Market Trends And Strategies
4. Preventive Vaccines Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Preventive Vaccines Growth Analysis And Strategic Analysis Framework
5.1. Global Preventive Vaccines PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Preventive Vaccines Market Growth Rate Analysis
5.4. Global Preventive Vaccines Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Preventive Vaccines Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Preventive Vaccines Total Addressable Market (TAM)
6. Preventive Vaccines Market Segmentation
6.1. Global Preventive Vaccines Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Live Or Attenuated Vaccines
Inactivated Vaccines
Toxoid Vaccines
Subunit Vaccines
Conjugate Vaccines
DNA Vaccines
Recombinant Vector Vaccines
6.2. Global Preventive Vaccines Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pneumococcal
Poliovirus
Hepatitis
Influenza
Measles
Rubella
Other Disease Types
6.3. Global Preventive Vaccines Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Pharmacies
Other Distribution Channels
6.4. Global Preventive Vaccines Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric
Adult
Geriatric
6.5. Global Preventive Vaccines Market, Sub-Segmentation Of Live or Attenuated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Measles, Mumps, and Rubella (MMR) Vaccine
Varicella (Chickenpox) Vaccine
Oral Polio Vaccine (OPV)
Yellow Fever Vaccine
Rotavirus Vaccine
Bacillus Calmette-Guerin (BCG) Vaccine
6.6. Global Preventive Vaccines Market, Sub-Segmentation Of Inactivated Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inactivated Poliovirus Vaccine (IPV)
Hepatitis A Vaccine
Rabies Vaccine
Influenza (Inactivated) Vaccine
Japanese Encephalitis Vaccine
6.7. Global Preventive Vaccines Market, Sub-Segmentation Of Toxoid Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Tetanus Toxoid Vaccine
Diphtheria Toxoid Vaccine
Pertussis (whooping cough) Vaccine
6.8. Global Preventive Vaccines Market, Sub-Segmentation Of Subunit Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hepatitis B Vaccine
Human Papillomavirus (HPV) Vaccine
Pertussis (acellular) Vaccine
Influenza (recombinant protein) Vaccine
6.9. Global Preventive Vaccines Market, Sub-Segmentation Of Conjugate Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pneumococcal Conjugate Vaccine (PCV)
Haemophilus influenzae type b (Hib) Vaccine
Meningococcal Conjugate Vaccine
6.10. Global Preventive Vaccines Market, Sub-Segmentation Of DNA Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Zika Virus DNA Vaccine
Cytomegalovirus (CMV) DNA Vaccine
Infectious Disease DNA Vaccines
6.11. Global Preventive Vaccines Market, Sub-Segmentation Of Recombinant Vector Vaccines, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ebola Vaccine (rVSV-ZEBOV)
COVID-19 Recombinant Vector Vaccines
Dengue Recombinant Vector Vaccines
7. Preventive Vaccines Market Regional And Country Analysis
7.1. Global Preventive Vaccines Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Preventive Vaccines Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
